Zydus Lifesciences Acquires Agenus Inc. Biologics Facilities and Establishes Zylidac Bio LLC Zydus Lifesciences has successfully acquired Agenus Inc.'s biologics manufacturing facilities, establishing Zylidac Bio LLC to enhance biopharmaceutical production in the U.S.

Zydus Lifesciences Acquires Agenus Inc. Biologics Facilities and Establishes Zylidac Bio LLC #India #Ahmedabad #CDMO #Zydus_Lifesciences #Agenus

France Expands Reimbursed Compassionate Access for Botensilimab/Balstilimab to Ovarian Cancer and Soft-Tissue Sarcomas - OncoDaily France expands reimbursed compassionate access to botensilimab/balstilimab for ovarian cancer and soft-tissue sarcomas under the AAC program.

France Expands Reimbursed Compassionate Access for Botensilimab/Balstilimab to Ovarian Cancer and Soft-Tissue Sarcomas

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #France #OvarianCancer #SoftTissueSarcomas #Agenus

France Grants Reimbursed Compassionate Access for BOT/BAL in Refractory MSS Colorectal Cancer - OncoDaily France grants reimbursed compassionate access to Agenus’ BOT/BAL for refractory MSS metastatic CRC, offering new hope for patients.

France Grants Reimbursed Compassionate Access for BOT/BAL in Refractory MSS Colorectal Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BOT/BAL #MSSCRC #ColorectalCancer #Agenus

BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing - OncoDaily BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing / Agenus, BATTMAN trial, botensilimab,

BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BOT/BAL #BATTMAN #Agenus #MiNK

Four Agenus Abstracts Have Been Accepted for Presentation at ESMO25 - OncoDaily Four Agenus Abstracts Have Been Accepted for Presentation at ESMO25 / Agenus, cancer, colorectal cancer, ESMO25, immunotherapy, OncoDaily, Oncology

Four Agenus Abstracts Have Been Accepted for Presentation at ESMO25
@myesmo.bsky.social

oncodaily.com/blog/esmo25-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Agenus #ESMO25

Agenus' Investigator's Forum 2025: BOT/BAL Advancing Immunotherapy in Solid Tumors - OncoDaily Agenus' Investigator's Forum 2025: BOT/BAL Advancing Immunotherapy in Solid Tumors / Agenus, Agenus' Investigator's Forum, Balstilimab, BATTMAN trial,

Agenus’ Investigator’s Forum 2025: BOT/BAL Advancing Immunotherapy in Solid Tumors

oncodaily.com/drugs/agenus...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Agenus #Investigator’sForum #BOT/BAL #Balstilimab #Botensilimab #ColorectalCancer #IO #Immunotherapy #SolidTumors

Garo Armen Shares a Personal Story Driving Agenus' Mission in Cancer Care - OncoDaily Garo Armen Shares a Personal Story Driving Agenus' Mission in Cancer Care / Agenus, cancer, Garo Armen, Headlines, National Cancer Survivor Month, OncoDaily,

Garo Armen Shares a Personal Story Driving Agenus’ Mission in Cancer Care

oncodaily.com/blog/garo-ar...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Agenus #NationalCancerSurvivorMonth

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology - OncoDaily Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology / Agenus, biotech, botensilimab, cancer, cancer care, Cancer

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology

oncodaily.com/opinion/agen...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Agenus #Zydus #IO #Immuno-Oncology

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL - OncoDaily Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL / Agenus, BOT/BAL, cancer,

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

oncodaily.com/insight/zydu...

#Agenus #BOT/BAL #Cancer #OncoDaily #Oncology #ZydusGroup #Health #Medicine

Zynext Ventures Invests in Agenus to Enhance Global Immuno-Oncology Portfolio Zynext Ventures has invested in Agenus Inc., boosting its immuno-oncology pipeline and supporting innovation in cancer therapies. This collaboration aims to accelerate treatment development for high-unmet need cancers.

Zynext Ventures Invests in Agenus to Enhance Global Immuno-Oncology Portfolio #United_States #Immuno-Oncology #Zynext_Ventures #Agenus #Pennington,_New_Jersey

Zydus Lifesciences Expands into Global Biologics CDMO Market Through Acquisition of Agenus Facilities Zydus Lifesciences is making a strategic move into the biologics CDMO sector, aiming to acquire Agenus' U.S. manufacturing facilities to enhance innovative therapy development.

Zydus Lifesciences Expands into Global Biologics CDMO Market Through Acquisition of Agenus Facilities #India #Ahmedabad #Biologics_CDMO #Zydus_Lifesciences #Agenus

Agenus shares leap on strategic collaboration with Zydus Lifesciences Investing.com -- Agenus Inc . (NASDAQ:AGEN) stock soared 30% following the announcement of a strategic collaboration with Zydus Lifesciences, which includes a $141 million deal to advance BOT/BAL and expand Zydus’ biologics manufacturing in the United States. The partnership agreement, which involves exchanging Agenus’ biologics CMC facilities in California for an upfront consideration of $75 million and up to an additional $50 million in contingent payments, has been designed to accelerate the clinical development and scale global manufacturing. Zydus will also launch a BioCDMO business in the U.S. with Agenus as its first customer, ensuring the manufacturing readiness of BOT/BAL for BLA submission and potential commercial launch. Furthermore, Agenus will receive a 5% royalty on net sales from Zydus in India and Sri Lanka, where Zydus will have the exclusive license to develop and commercialize these therapies. Additionally, Zydus will make a strategic equity investment in Agenus by purchasing approximately 2.1 million shares at $7.50 per share, totaling around $16 million. The CEO of Agenus, Dr. Garo Armen, highlighted the trade agreement between the United States and India as a positive step towards strengthening Indian-American relations and ensuring secure biopharma supply chains. He expressed confidence in the partnership’s potential to accelerate future clinical trials and expand the global oncology therapeutics footprint of BOT/BAL. Dr. Sharvil Patel, Managing Director at Zydus Lifesciences, expressed enthusiasm for the partnership, noting the potential benefits for patients in India, Sri Lanka, and globally. Zydus plans to conduct clinical trials for BOT/BAL in various stages of disease and expand its use beyond colorectal cancer to other significant diseases such as triple-negative breast cancer. The transaction is subject to customary closing conditions and due diligence, with the parties expecting to complete closing agreements within 60 days. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Agenus #ZydusLifesciences #Pharmaceuticals #Biotech #StockMarket

Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025 - OncoDaily Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025 / Agenus, cancer, ESMO GI 2025, FDA, Headlines, OncoDaily,

Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025
@fda.gov @myesmo.bsky.social

oncodaily.com/blog/agenus-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Agenus #FDA #ESMO-GI2025 #ESMO

Agenus Names Leading GI Oncologist Dr. Richard Goldberg as Chief Development Officer - OncoDaily Agenus Names Leading GI Oncologist Dr. Richard Goldberg as Chief Development Officer / cancer, colorectal cancer, Garo Armen, GI oncology, OncoDaily,

Agenus Names Leading GI Oncologist Dr. Richard Goldberg as Chief Development Officer

oncodaily.com/insight/agen...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Agenus #GI

Agenus Bets Big on Botensilimab - OncoDaily Agenus Bets Big on Botensilimab / 10 most promising drugs, Agenus, botensilimab, cancer, fda aproval, Headlines, OncoDaily, Oncology

Agenus Bets Big on Botensilimab

oncodaily.com/opinion/agen...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Agenus #Botensilimab

Breelyn Wilky Discusses Promising Phase 1 Results of BOT/BAL in Advanced Sarcomas - Agenus - OncoDaily Breelyn Wilky Discusses Promising Phase 1 Results of BOT/BAL in Advanced Sarcomas - Agenus / Agenus, Breelyn Wilky, cancer, OncoDaily, Oncology

Agenus - Breelyn Wilky Discusses Promising Phase 1 Results of BOT/BAL in Advanced Sarcomas

oncodaily.com/blog/breelyn...

#Cancer #CancerResearch #Agenus #CancerTreatment #Sarcoma #Medicine #Health #Oncology #OncoDaily

Agenus partners with Fight Colorectal Cancer to drive awareness and action for CRC - OncoDaily Agenus partners with Fight Colorectal Cancer to drive awareness and action for CRC / Agenus, cancer, colorectal cancer, Colorectal Cancer Awareness Month,

Agenus partners with Fight Colorectal Cancer to drive awareness and action for CRC
@fightcrc.bsky.social

oncodaily.com/blog/252531

#Cancer #Collaboration #Medicine #Health #ColorectalCancer #CRC #Agenus #Oncology #OncoDaily

Recognizing Colorectal Cancer Awareness Month - Agenus - OncoDaily Recognizing Colorectal Cancer Awareness Month - Agenus / Agenus, cancer, colorectal cancer, Colorectal Cancer Awareness Month, CRC, OncoDaily, Oncology

Agenus - Recognizing Colorectal Cancer Awareness Month

oncodaily.com/blog/colorec...

#Cancer #ColorectalCancer #Medicine #Health #ColorectalCancerAwarenessMonth #Agenus #Oncology #OncoDaily

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas - OncoDaily Learn how a novel combination of Botensilimab and Balstilimab demonstrates promising efficacy in traditionally immunotherapy-resistant sarcomas.

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

oncodaily.com/oncolibrary/...

#10MostPromisingCancerDrugs #Agenus #Angiosarcoma #ASCO #Botensilimab #CancerCare #CancerResearch #Immunotherapy #Sarcoma #SarcomaResearch #Health #Medicine #NewPaperAlert

Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers - OncoDaily Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers / Agenus, botensilimab, cancer, colorectal cancer, Dhan Chand,

Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers

oncodaily.com/dialogues/bo...

#Agenus #Botensilimab #Cancer #ColorectalCancer #GlobalCancerMovement #OncoDaily #Oncology

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL - OncoDaily Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL / Agenus, Balstilimab, botensilimab, cancer, OncoDaily, Oncology, Tanner Pharma Group

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

oncodaily.com/insight/203713

#Agenus #Balstilimab #Botensilimab #Cancer #OncoDaily #Oncology #TannerPharmaGroup #Medicine #Health

Gevorg Tamamyan: 80 speakers and around 450 participants from 30 countries - OncoDaily Gevorg Tamamyan: 80 speakers and around 450 participants from 30 countries / Agenus, cancer, colorectal cancer, Gevorg Tamamyan, OncoDaily, Oncology

80 speakers and around 450 participants from 30 countries - Gevorg Tamamyan

oncodaily.com/insight/gevo...

@gevorgtamamyan.bsky.social

#Agenus #Cancer #ColorectalCancer #OncoDaily #Oncology #Medicine #Health